Adrenal Crisis on Combination Checkpoint Inhibitor Therapy: Primary or Secondary, and When to Treat
A single patient in acute adrenal crisis on combination checkpoint inhibitor therapy, where a single lab abnormality argues against the epidemiologically more likely diagnosis before confirmatory testing returns.
Wendell A., a 61-year-old retired postal worker, is four cycles into combination ipilimumab and nivolumab for metastatic melanoma that has, so far, been shrinking on every scan — a genuine success his oncologist has been careful not to jinx by saying so out loud. His wife has kept a small notebook logging each infusion date and how he felt afterward, a habit she started after his first cycle left him more fatigued than either of them expected, and it was her notebook, flipped open at the bedside, that first made the team realize this hospitalization's fatigue was categorically different from his usual post-infusion tiredness. He was admitted yesterday with three days of worsening fatigue, nausea, and a systolic blood pressure that dropped to 82 in triage, hyponatremic at 128 and mildly hyperkalemic at 5.4. An 8 a.m. cortisol came back at 2.1 mcg/dL, unambiguously low, confirming adrenal insufficiency as the cause — but the ACTH level that would say whether this is primary adrenalitis or secondary insufficiency from hypophysitis is still pending, and the two have real, different immediate management implications that can't simply wait for the result.
The epidemiology cuts against him having the more dramatic-sounding diagnosis: primary adrenalitis from checkpoint inhibitors is rare, occurring in under 2% of patients even on combination therapy, while hypophysitis with secondary adrenal insufficiency is far more common — reported by Barroso-Sousa et al.'s meta-analysis in roughly 6 to 10% of patients on combination ipilimumab-nivolumab specifically. But rare doesn't mean impossible, and his potassium of 5.4 is itself a real clue pointing the other way: hyperkalemia reflects aldosterone deficiency, which only happens with primary adrenal disease, since secondary insufficiency from a pituitary problem leaves the renin-angiotensin-aldosterone system intact. That one lab value is already doing more diagnostic work than the pending ACTH result will add once it arrives.
Bedside, hour 4, ACTH result still pending
His potassium is 5.4. Secondary insufficiency doesn't do that — the renin-angiotensin-aldosterone system is intact in hypophysitis, so hyperkalemia specifically points toward primary adrenal disease. I'd start hydrocortisone and fludrocortisone both now rather than wait for ACTH to confirm what this lab value is already telling us.
I hear the potassium point, but on combination ipilimumab-nivolumab, hypophysitis with secondary insufficiency happens, on Barroso-Sousa's meta-analysis, in six to ten percent of patients, against under two percent for primary adrenalitis — a real, large epidemiologic gap. I'd start hydrocortisone now, which he needs regardless of which one this is, but hold fludrocortisone until ACTH confirms primary disease, since unnecessary mineralocorticoid replacement carries its own volume and blood pressure risk in a diagnosis we haven't actually confirmed.
Grant me the potassium and it still doesn't settle the timing. Hydrocortisone at stress dose carries enough mineralocorticoid activity of its own to cover him for the next several hours, which is all the time the ACTH needs. If it comes back suppressed, we've added a drug he never required.
I'd weigh this differently. The cost of starting fludrocortisone now versus waiting a few hours for ACTH is low — it's a well-tolerated drug we can stop just as easily if the result comes back showing secondary disease. The cost of under-treating a true primary adrenal crisis in a hemodynamically unstable patient is not low. Given a specific, present lab abnormality pointing one direction, I'd rather start both now and reconsider the fludrocortisone specifically once ACTH returns, than wait on a base rate when the labs in front of us say something more specific.
Agreed: start hydrocortisone and fludrocortisone both now, given the hemodynamic instability and the potassium's specific implication, with the fludrocortisone reassessed once ACTH results return.
Not agreed: whether to resume immunotherapy once he's stable, and how soon. The oncologist, given how well his melanoma is responding, would resume relatively quickly once hormone replacement is established; the endocrinologist wants a longer stabilization period first, given how acute and severe this presentation was, before reintroducing a drug that may have caused it.